Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation
Taro Hitosugi,Lu Zhou,Jun Fan,Shannon Elf,Liang Zhang,Jianxin Xie,Yi Wang,Ting-Lei Gu,Masa Alečković,Gary LeRoy,Yibin Kang,Hee-Bum Kang,Jae-Ho Seo,Changliang Shan,Peng Jin,Weimin Gong,Sagar Lonial,Martha L. Arellano,Hanna J. Khoury,Georgia Z. Chen,Dong M. Shin,Fadlo R. Khuri,Titus J. Boggon,Sumin Kang,Chuan He,Jing Chen
DOI: https://doi.org/10.1038/ncomms2759
IF: 16.6
2013-01-01
Nature Communications
Abstract:How oncogenic signalling coordinates glycolysis and anabolic biosynthesis in cancer cells remains unclear. We recently reported that the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) regulates anabolic biosynthesis by controlling intracellular levels of its substrate 3-phosphoglycerate and product 2-phosphoglycerate. Here we report a novel mechanism in which Y26 phosphorylation enhances PGAM1 activation through release of inhibitory E19 that blocks the active site, stabilising cofactor 2,3-bisphosphoglycerate binding and H11 phosphorylation. We also report the crystal structure of H11-phosphorylated PGAM1 and find that phospho-H11 activates PGAM1 at least in part by promoting substrate 3-phosphoglycerate binding. Moreover, Y26 phosphorylation of PGAM1 is common in human cancer cells and contributes to regulation of 3-phosphoglycerate and 2-phosphoglycerate levels, promoting cancer cell proliferation and tumour growth. As PGAM1 is a negative transcriptional target of TP53 , and is therefore commonly upregulated in human cancers, these findings suggest that Y26 phosphorylation represents an additional acute mechanism underlying phosphoglycerate mutase 1 upregulation.